#1 Clinical Trials Search in Europe

Oxazepam

Oxazepam, a benzodiazepine medication, has been the subject of several clinical trials investigating its potential uses and effects in various medical conditions. These trials have explored oxazepam’s role in treating alcohol withdrawal syndrome, cocaine addiction, and its interactions with other medications. Researchers have also examined its safety profile and pharmacokinetics in different patient populations, including those with HIV infections and gerontopsychiatric patients.

Table of Contents

What is Oxazepam?

Oxazepam is a medication that belongs to a class of drugs called benzodiazepines. It is also known by the brand name Serax[3]. Benzodiazepines are among the most frequently prescribed classes of drugs and are commonly used for patients with chronic diseases[2].

This medication works by affecting certain chemicals in the brain to produce a calming effect. It is primarily used to treat anxiety disorders and manage symptoms of alcohol withdrawal[1].

Medical Uses

Oxazepam is prescribed for several medical conditions, including:

  • Anxiety Disorders: It helps reduce feelings of anxiety and nervousness[4].
  • Alcohol Withdrawal Syndrome: Oxazepam is used to manage symptoms that occur when a person stops drinking alcohol after long-term or heavy use[1].
  • Insomnia: In some cases, it may be prescribed to help with sleep problems[5].

How Oxazepam Works

Oxazepam works by enhancing the effects of a natural chemical in the body called gamma-aminobutyric acid (GABA). GABA is a neurotransmitter that helps to calm the brain and nervous system. By increasing GABA’s effects, oxazepam produces a sedative and anxiety-reducing effect[1].

Dosage and Administration

The dosage of oxazepam can vary depending on the condition being treated and the individual patient’s needs. Here are some general guidelines based on the studies reviewed:

  • For Alcohol Withdrawal Syndrome: A typical dosage might be 60mg three times daily for the first few days, gradually reducing over a period of about 10 days[1].
  • For Anxiety: Dosages can range from 10mg to 30mg, taken two to four times daily[6].

It’s important to note that these are just examples, and your doctor will prescribe the appropriate dosage for your specific situation. Always follow your doctor’s instructions and never adjust your dosage without consulting them first.

Side Effects and Safety

Like all medications, oxazepam can cause side effects. Common side effects may include:

  • Drowsiness or sleepiness
  • Dizziness
  • Confusion
  • Headache
  • Nausea

In some cases, more serious side effects can occur. These may include changes in mood or behavior, memory problems, or signs of an allergic reaction. If you experience any severe or unusual symptoms, contact your healthcare provider immediately[4].

It’s important to note that oxazepam can be habit-forming, especially when used for long periods or in high doses. Your doctor will carefully monitor your use of this medication[3].

Drug Interactions

Oxazepam can interact with other medications, potentially altering their effects or increasing the risk of side effects. Some notable interactions include:

  • Zidovudine (AZT): A study investigated the potential interaction between oxazepam and zidovudine, an HIV medication. This research highlights the importance of monitoring for potential interactions in patients taking multiple medications[2].
  • Other Central Nervous System Depressants: Combining oxazepam with other medications that cause drowsiness or slow breathing can increase these effects. This includes alcohol, other benzodiazepines, and certain pain medications[6].

Always inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions.

Current Research and Studies

Oxazepam continues to be the subject of various research studies:

  • Alcohol Withdrawal Treatment: A study compared the effectiveness of oxazepam to gamma-hydroxybutyrate (GHB) in treating alcohol withdrawal syndrome. This research aims to find the most effective treatments for this condition[1].
  • Combination Therapy for Addiction: Researchers are investigating the potential of combining oxazepam with other medications, such as metyrapone, for treating cocaine and tobacco addiction[3][6].
  • Safety in Elderly Patients: A study is examining the safety of various psychotropic medications, including oxazepam, in elderly psychiatric patients. This research is crucial for understanding how these medications affect older adults[4].

These ongoing studies demonstrate the continued interest in understanding and improving the use of oxazepam in various medical contexts.

Aspect Details
Conditions Studied Alcohol withdrawal syndrome, cocaine addiction, tobacco use disorder, HIV infections
Study Designs Randomized, double-blind, placebo-controlled, comparative studies
Comparators Placebo, gamma-hydroxybutyric acid (GHB), combination with metyrapone
Primary Outcomes Reduction in withdrawal symptoms, drug craving, safety and tolerability
Secondary Outcomes Pharmacokinetics, cognitive function, quality of life, sleep quality
Safety Assessments Adverse events, physical examinations, vital signs, ECG, laboratory tests
Special Populations HIV-infected patients, gerontopsychiatric patients, tobacco smokers
Drug Interactions With zidovudine (AZT), metyrapone

FAQ

  • What conditions are being studied in clinical trials involving oxazepam? Clinical trials involving oxazepam are studying its potential in treating various conditions, including alcohol withdrawal syndrome, cocaine addiction, and tobacco use disorder. Some trials are also investigating its interactions with other medications and its safety profile in specific patient populations.
  • How is oxazepam being compared to other treatments in clinical trials? In some trials, oxazepam is being compared to other treatments. For example, one study compares the efficacy of gamma-hydroxybutyric acid (GHB) to oxazepam in treating alcohol withdrawal syndrome. Another trial compares a combination of metyrapone and oxazepam to placebo in treating cocaine addiction.
  • What are researchers looking at regarding oxazepam's safety? Researchers are examining oxazepam's safety profile through various measures, including monitoring adverse events, physical examinations, vital signs, ECG readings, and laboratory tests. Some studies are specifically focusing on the safety of oxazepam in elderly patients or those with specific conditions like HIV infections.
  • Are there any studies looking at oxazepam's interactions with other drugs? Yes, some studies are investigating oxazepam's interactions with other medications. For instance, one trial is examining the pharmacokinetic interaction between oxazepam and zidovudine (AZT) in HIV-infected patients. Another study is looking at the combination of metyrapone and oxazepam in treating cocaine addiction.
  • What outcomes are being measured in oxazepam clinical trials? Clinical trials involving oxazepam are measuring various outcomes, including reduction in withdrawal symptoms, drug craving, drug use, safety and tolerability, pharmacokinetics, cognitive function, and quality of life. Some studies also assess the presence of hangover effects and the impact on sleep quality.

Ongoing Clinical Trials on Oxazepam

  • Study on the Effects of GT-002 and Oxazepam for Cognitive Impairment in Schizophrenia Patients

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Psilocybin for Relieving Chronic Neuropathic Pain in Patients with Chemotherapy-Induced Peripheral Neuropathy

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study of diazepam and oxazepam in patients with benzodiazepine and opioid dependence who are receiving opioid agonist therapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    Norway

  • Comparison of Oxazepam 50 mg orodispersible tablets and Oxazepam 50 mg standard tablets in healthy volunteers to test if they work the same way in the body

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Portugal

  • Study on the Bioequivalence of Oxazepam 10 mg Orodispersible Tablets Compared to Standard Tablets in Healthy Volunteers

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Portugal

Glossary

  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. This helps researchers understand how the body processes the medication.
  • Benzodiazepines: A class of drugs that act on the central nervous system, producing sedation, reducing anxiety, and relaxing muscles. Oxazepam belongs to this class of medications.
  • Placebo: A substance with no active therapeutic effect, used as a control in clinical trials to test the effectiveness of new drugs or treatments.
  • Double-blind study: A research design where neither the participants nor the researchers directly involved know who is receiving the experimental treatment and who is receiving the placebo or standard treatment.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
  • Craving: An intense, urgent, or abnormal desire or longing, often associated with addiction to substances like drugs or alcohol.
  • Alcohol Withdrawal Syndrome: A set of symptoms that can occur when a person who has been drinking heavily for a prolonged period suddenly stops or significantly reduces their alcohol intake.
  • Efficacy: The ability of a drug or treatment to produce the desired effect under ideal circumstances in clinical trials.

References

  1. https://clinicaltrials.gov/study/NCT02090504
  2. https://clinicaltrials.gov/study/NCT00000661
  3. https://clinicaltrials.gov/study/NCT00567814
  4. https://clinicaltrials.gov/study/NCT02374567
  5. https://clinicaltrials.gov/study/NCT02273453
  6. https://clinicaltrials.gov/study/NCT02406066